Naloxone Co-prescribing to Patients Receiving Prescription Opioids in the Medicare Part D Program, United States, 2016-2017

Christopher M Jones; Wilson Compton; Meena Vythilingam; Brett Giroir

doi:10.1001/jama.2019.7988

Naloxone Co-prescribing to Patients Receiving Prescription Opioids in the Medicare Part D Program, United States, 2016-2017

JAMA. 2019 Aug 6;322(5):462-464. doi: 10.1001/jama.2019.7988.

Authors

Christopher M Jones¹, Wilson Compton², Meena Vythilingam³, Brett Giroir³

Affiliations

¹ Centers for Disease Control and Prevention, Atlanta, Georgia.
² National Institutes of Health, Bethesda, Maryland.
³ US Department of Health and Human Services, Washington, DC.

Abstract

This study uses Medicare Part D data to compare US national and state rates of co-prescribing of naloxone with opioids and benzodiazepines in 2016-2017.

MeSH terms

Analgesics, Opioid / therapeutic use*
Benzodiazepines / therapeutic use*
Drug Prescriptions / statistics & numerical data*
Drug Therapy, Combination / statistics & numerical data
Government Regulation
Humans
Medicare Part D
Naloxone / therapeutic use*
Practice Patterns, Physicians' / statistics & numerical data
United States

Substances

Analgesics, Opioid
Benzodiazepines
Naloxone